This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

• In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).

• SVB Leerink views these results as 'strong' and says they provide a clear win for the company as all doses of pegoza demonstrated statistically significant and clinically meaningful reductions in triglycerides, exceeding KOL expectations ahead of the results.

• The analysts say that pegoza's safety/tolerability profile continues to look favorable vs. Akero Therapeutics Inc's (NASDAQ: AKRO) efruxifermin, with lower rates of GI toxicity (diarrhea, nausea, vomiting) and no apparent CNS/tremor signal.

• SVB has updated its model to reflect a higher probability of success (70% from 35%) and higher peak sales (~$700 million from ~$660 million) in SHTG based on the Phase 2 results and the latest equity offering.

• The analyst has lowered the price target to $29 from $50 and reiterates the Out-Perform rating.

• "Overall, we continue to view pegozafermin as a potentially best-in-class FGF21 analog, based on its competitive efficacy profile — now shown across multiple indications — and emerging differentiation on safety/ tolerability," SVB wrote.

• Price Action: ETNB shares are down 4.48% at $3.41 during the market session on the last check Monday.

Latest Ratings for ETNB

Date	Firm	Action	From	To
Dec 2021	HC Wainwright & Co.	Initiates Coverage On		Buy
Oct 2021	Cantor Fitzgerald	Assumes		Overweight
Aug 2021	RBC Capital	Maintains		Outperform

View More Analyst Ratings for ETNB

View the Latest Analyst Ratings

See more from Benzinga

• The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

• The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.